With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
This article was originally published in The Pink Sheet Daily
Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.
You may also be interested in...
Already strong in both CNS and cardiovascular drugs, Forest obtained an option to license the Pennsylvania start-up’s lead program in acute heart failure. In the process, Forest took a stake in Trevena as the young company shifts its focus toward pain drugs based on Nobel Prize-winning research.
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
The biotech has forged a partnership with NIH to discover and begin development of a biased ligand to the delta opioid receptor for the treatment of MDD.